BIOMAT Database Logo BIOMAT Database Logo

A Vaccine against Ebola Virus. 2020

Erica Ollmann Saphire
La Jolla Institute for Immunology, La Jolla, CA, USA. Electronic address: erica@lji.org.

Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018-2020 outbreak of disease. To view this Bench to Bedside, open or download the PDF.

UI MeSH Term Description Entries
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D017277 Drug Approval Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug. Drug Approval Process,New Drug Approval,Food and Drug Administration Drug Approval,Food and Drug Administration Drug Approval Process,New Drug Approval Process,Approval Process, Drug,Approval Processes, Drug,Approval, Drug,Approval, New Drug,Approvals, Drug,Approvals, New Drug,Drug Approval Processes,Drug Approval, New,Drug Approvals,Drug Approvals, New,New Drug Approvals,Process, Drug Approval,Processes, Drug Approval
D046129 Ebola Vaccines Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER. Ebola Vaccine,Ebola Virus Vaccine,Ebola Virus Vaccines,Ebolavirus Vaccine,Ebolavirus Vaccines,Vaccine, Ebola,Vaccine, Ebola Virus,Vaccine, Ebolavirus,Vaccines, Ebola,Vaccines, Ebola Virus,Vaccines, Ebolavirus,Virus Vaccine, Ebola,Virus Vaccines, Ebola
D019142 Hemorrhagic Fever, Ebola A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS. Ebola Hemorrhagic Fever,Ebola Virus Disease,Ebolavirus Infection,Ebola Infection,Ebola Virus Infection,Ebolavirus Infections,Infection, Ebola,Infection, Ebola Virus,Infection, Ebolavirus,Infections, Ebolavirus,Virus Infection, Ebola
D029043 Ebolavirus A genus in the family FILOVIRIDAE consisting of several distinct species of Ebolavirus, each containing separate strains. These viruses cause outbreaks of a contagious, hemorrhagic disease (HEMORRHAGIC FEVER, EBOLA) in humans, usually with high mortality. Cote d'Ivoire ebola virus,Ebola Virus, Cote d'Ivoire,Ebola Virus, Reston,Ebola Virus, Sudan,Ebola Virus, Zaire,Ebola Virus,Ebola-like Viruses,Reston Ebola Virus,Sudan Ebola Virus,Zaire Ebola Virus,Ebola Viruses,Ebola like Viruses,Ebola-like Virus,Ebolaviruses,Virus, Ebola,Viruses, Ebola
D032541 Mass Vaccination Administration of a vaccine to large populations in order to elicit IMMUNITY. Mass Immunization,Immunization, Mass,Mass Immunizations,Mass Vaccinations,Vaccination, Mass

Related Publications

Erica Ollmann Saphire
Towards a vaccine against Ebola virus.
December 2003, Expert review of vaccines,
Erica Ollmann Saphire
[Hope for a vaccine against ebola virus].
January 2001, Pharmazie in unserer Zeit,
Erica Ollmann Saphire
Experimental vaccine protects monkeys against Ebola virus.
January 2001, Bulletin of the World Health Organization,
Erica Ollmann Saphire
A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
November 2018, The Journal of infectious diseases,
Erica Ollmann Saphire
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
March 2006, Virology,
Erica Ollmann Saphire
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
November 2007, The Journal of infectious diseases,
Erica Ollmann Saphire
[Potential vaccine candidates against Ebola and the first vaccine against chikungunya virus infection].
August 2014, Revue medicale suisse,
Erica Ollmann Saphire
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
August 2011, PLoS neglected tropical diseases,
Erica Ollmann Saphire
In silico-based vaccine design against Ebola virus glycoprotein.
January 2017, Advances and applications in bioinformatics and chemistry : AABC,
Erica Ollmann Saphire
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
December 2011, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!